Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
NCT ID: NCT06889350
Last Updated: 2025-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
40 participants
INTERVENTIONAL
2025-03-26
2025-05-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
NCT06339788
Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
NCT07102719
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
NCT04706286
Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic of CKD-501, D745, and D150 for Healthy Subjects in Fed State.
NCT06483243
A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.
NCT04810676
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HD-P023
One tablet of HD-P023 by oral
HD-P023
Single dose administration of HD-P023
Co-administration of Teneligliptin and Empagliflozin High
One tablet each of Teneligliptin and Empagliflozin High by oral
Teneligliptin
Single does administration of Teneligliptin and Empagliflozin High
Empagliflozin High
Single does administration of Teneligliptin and Empagliflozin High
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HD-P023
Single dose administration of HD-P023
Teneligliptin
Single does administration of Teneligliptin and Empagliflozin High
Empagliflozin High
Single does administration of Teneligliptin and Empagliflozin High
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed informed consent
* Healthy Volunteer
* Other inclusion applies
Exclusion Criteria
* Other exclusion applied
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Handok Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H Plus Yangji Hospital
Seoul, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HD-MP-108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.